In conclusion, our study highlights the therapeutic effects and mechanisms of the treatment on NAFLD via combinatorial application: gut microbiota (GM), and Avena sativa (AS), indicating antagonists (myricetin, quercetin, diosgenin, and vestitol) to inhibit PI3K-Akt signaling pathway. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.